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ABSTRACT 28 
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 29 
The Novel Bacterial Topoisomerase Inhibitor class is an investigational type of 30 
antibacterial inhibitor of DNA gyrase and topoisomerase IV that do not have cross-31 
resistance with the quinolones. Here, we report the evaluation of the in vitro properties 32 
of a new series of this type of small-molecule. Exemplar compounds selectively and 33 
potently inhibited the catalytic activities of Escherichia coli DNA gyrase and 34 
topoisomerase IV but did not block the DNA breakage-reunion step. Compounds 35 
showed broad-spectrum bactericidal activity against a wide range of Gram-positive and 36 
Gram-negative pathogens, including biodefence microorganisms, and Mycobacterium 37 
tuberculosis. No cross-resistance with quinolone-resistant Staphylococcus aureus and 38 
E. coli isolates was observed. Measured MIC90 values were 4 and 8 µg/mL against a 39 
panel of contemporary multidrug-resistant isolates of Acinetobacter baumannii and E. 40 
coli. In addition, representative compounds exhibited greater antibacterial potency 41 
than the quinolones against obligate anaerobic species. Spontaneous mutation rates 42 
were low, with frequencies-of-resistance typically <10-08 against E. coli and A. 43 
baumannii at concentrations equivalent to four-fold the MIC. Compound-resistant E. 44 
coli mutants isolated following serial passage were characterised by whole-genome 45 
sequencing and carried a single Arg38Leu amino acid substitution in the GyrA subunit 46 
of DNA gyrase. Preliminary in vitro safety data indicate that the series shows a 47 
promising therapeutic index and potential for low hERG inhibition (IC50 >100 µM). In 48 
summary, the compounds’ distinct mechanism-of-action relative to the 49 
fluoroquinolones, whole-cell potency, low potential for resistance development and 50 
favourable in vitro safety profile warrant their continued investigation as potential 51 
broad-spectrum antibacterial agents. 52 
 53 
 54 
 55 
INTRODUCTION 56 
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 57 
Bacterial infections are becoming increasingly untreatable owing to the rapid emergence of 58 
multidrug resistance as well as the limited number of novel antibacterial agents in clinical 59 
development (1, 2, 3). The United States Centers for Disease Control and Prevention (CDC) 60 
recently identified 15 antibiotic-resistant microorganisms as posing a threat to human health 61 
classified as ‘Urgent’ or ‘Serious’ (4). Prominent amongst this set are antibiotic-resistant 62 
strains of the ‘ESKAPE’ group of species (1), such as carbapenem-resistant 63 
Enterobacteriaceae (CRE), multi-drug-resistant (MDR) Acinetobacter, MDR Pseudomonas 64 
aeruginosa, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant 65 
Enterococcus (VRE). Also in the list are the Gram-positive anaerobe Clostridium difficile, drug-66 
resistant Neisseria gonorrhoeae and drug-resistant tuberculosis. 67 
 68 
The urgent need to discover and develop new antibacterial agents to counter the threat of 69 
drug-resistant infections is widely recognised. Research efforts over the past few years have 70 
focused on the development of novel classes of antibacterials with a dual-targeting 71 
mechanism-of-action distinct from currently-used antibiotics, with the twin objectives of 72 
avoiding cross-resistance and reducing the emergence of de novo resistance. The essential 73 
bacterial type II topoisomerase enzymes, DNA gyrase and topoisomerase IV, are well-74 
validated drug targets for antibiotic pharmacology by the (fluoro)quinolone and aminocoumarin 75 
classes (5, 6, 7, 8). These enzymes are responsible for introducing negative supercoils into 76 
DNA and for the decatenation of DNA. The high degree of sequence similarity between DNA 77 
gyrase and topoisomerase IV offers the prospect of multi-targeting with a single 78 
pharmacophore (9, 10). Despite the now widespread resistance to the quinolones, the type II 79 
topoisomerases continue to provide opportunities for antibacterial discovery based on 80 
exploiting novel binding interactions between new chemical ligands and the target enzymes 81 
in order to bypass mutations associated with quinolone resistance. Selected examples of this 82 
strategy are the 2-aminoquinazolinedione (11), the isothiazoloquinolone (12), the 83 
spiropyrimidinetrione (13) and the novel tricyclic topoisomerase inhibitor (14) classes.    84 
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 85 
One emerging class of non-quinolone inhibitors of DNA gyrase and topoisomerase IV is the 86 
Novel Bacterial Topoisomerase Inhibitor (NBTI) type. NBTI molecules bind a site distinct from, 87 
but adjacent to, the catalytic centre of DNA gyrase/topoisomerase IV that is occupied by the 88 
quinolones (15). Consequently, NBTI compounds retain potency against quinolone-resistant 89 
isolates. Structurally, NBTI molecules comprise a northern head moiety that interacts with the 90 
DNA, a central linker portion, and a southern group that binds to the enzymes. A number of 91 
advanced NBTI molecules have been described in the literature, including NXL101 (16), 92 
AZD9742 (17), NBTI 5463 (18) and gepotidacin, (19), which is currently undergoing Phase II 93 
human clinical evaluation. The NBTI pharmacophore has been associated with cardiovascular 94 
and other safety liabilities (17, 20, 21, 22, 23). A key aim in the development of NBTIs, 95 
therefore, is achieving broad antibacterial potency, including against challenging Gram-96 
negative pathogens, whilst maintaining satisfactory pharmacokinetics and safety margins.   97 
 98 
Towards this goal, Redx Pharma recently disclosed a new series of NBTI type compounds 99 
characterised by a novel tricyclic LHS moiety (A. Ratcliffe, I. Cooper, M. Pichowicz, N. Stokes, 100 
C. Charrier, 18 February 2016, International Patent Application Number WO 2016/024096). 101 
The chemical structures of six selected compounds from this series are displayed in Figure 1. 102 
The purpose of this present study was to undertake a detailed in vitro biological evaluation of 103 
exemplar compounds from the series. Specifically, their ability to inhibit DNA gyrase and 104 
topoisomerase IV activities; their whole-cell potency against panels of wild-type and 105 
quinolone-resistant bacteria, including clinically-important anaerobes and biodefence 106 
organisms; and their in vitro safety profiles were assessed and are reported.  107 
 108 
 109 
MATERIALS AND METHODS 110 
 111 
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Reagents and media. Proprietary compounds were prepared at Redx Pharma as described 112 
in International Patent Application WO 2016/024096. Reference antibiotics were purchased 113 
from Sigma Aldrich (Dorset, UK). Bacteriological media were purchased from Oxoid Ltd 114 
(Basingstoke, UK).  115 
 116 
Bacterial strains. The bacteria used in this study were obtained from the American Type 117 
Culture Collection (ATCC, Middlesex, United Kingdom), the Network on Antibacterial 118 
Resistance in Staphylococcus aureus (Manassas, Virginia) or the Coli Genetic Stock Center 119 
(New Haven, Connecticut). Escherichia coli strains MG1655 WT, MG1655 S83L and MG1655 120 
D87G were provided by Professor Tony Maxwell (John Innes Centre, Norwich, United 121 
Kingdom). E. coli ECCPX1-SP25 was selected and characterised at Redx Pharma by the 122 
serial passage of E. coli ATCC 25922 in the presence of ciprofloxacin as described (V. 123 
Savage, C. Charrier, N. Stokes, 18 February 2016, International Patent Application Number 124 
WO 2016/024098).  125 
 126 
DNA supercoiling, decatenation and cleavage complex. DNA supercoiling, decatenation 127 
and cleavage complex assays were all performed by Inspiralis Ltd (Norwich, United Kingdom) 128 
using a gel-based assay format. Briefly, one unit of E. coli DNA gyrase was incubated with 0.5 129 
µg of relaxed pBR322, and one unit of topoisomerase IV or human topoisomerase II was 130 
incubated with 200 ng kDNA, all in a reaction volume of 30 µL at 37 °C for 30 min in the 131 
presence of a series of concentrations of the test compound. Human topoisomerase II activity 132 
was assessed in the presence of 100 µM of test compound. Supercoiling reactions were 133 
conducted under the following conditions: 35 mM Tris.HCl (pH 7.5), 24 mM KCl, 4 mM MgCl2, 134 
2 mM DTT, 1.8 mM Spermidine, 1 mM ATP, 6.5% (w/v) glycerol and 0.1 mg/ml BSA. E. coli 135 
topoisomerase IV decatenation reactions were conducted under the following conditions: 50 136 
mM HEPES-KOH (pH 7.6), 100 mM potassium glutamate, 10 mM magnesium acetate, 10 mM 137 
dithiothreitol, 1 mM ATP and 50 μg/ml BSA. Inhibition of human topoisomerase II decatenation 138 
activity was assessed as described previously (Savage et al, 2016). Reactions were stopped 139 
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using 30 μL chloroform/iso-amyl alcohol (26:1) and 20 μL Stop Dye (40 % sucrose, 100 mM 140 
Tris.HCl [pH 7.5], 1 mM EDTA, 0.5 μg/mL bromophenol blue). Topoisomers were visualised 141 
by ethidium bromide staining, resolved and quantified by gel electrophoresis and the band 142 
intensities analysed by gel documentation equipment (Syngene, Cambridge, UK) and 143 
quantified using Syngene Gene Tools software. Raw data were converted to a percentage of 144 
the inhibitor-free control and were analysed using SigmaPlot Version 12.5. Non-linear 145 
regression was used to calculate the half-inhibitory concentrations (IC50). The human 146 
topoisomerase II inhibitor, etoposide, was used as a positive control for inhibition for this 147 
assay. For cleavage complex assays, compounds were tested at 100 μM in a final DMSO 148 
concentration of 1% (v/v). E. coli DNA gyrase (one unit) was incubated with 0.5 μg of 149 
supercoiled pBR322 DNA at 37 °C for 30 min. Reactions were performed in a volume of 30 150 
µL using the following conditions: 35 mM Tris.HCl (pH 7.5), 24 mM KCl, 4 mM MgCl2, 2 mM 151 
DTT, 1.8 mM Spermidine, 6.5% (w/v) glycerol and 0.1 mg/mL BSA. Following this, reactions 152 
were incubated for 30 min with 0.2 % SDS and 0.5 μg/μL proteinase K. Reactions were 153 
stopped in the same manner as for the supercoiling and decatenation assays. Topoisomers 154 
and cleavage products were visualised by gel electrophoresis. Cleavage products were 155 
expressed as a percentage of the fully supercoiled inhibitor-free control as described for the 156 
supercoiling and decatenation assays. 157 
 158 
Antibacterial susceptibility testing. MICs were determined by the broth microdilution 159 
procedure according to the guidelines of the Clinical and Laboratory Standards Institute M07-160 
A10 (24). The broth microdilution method involved a two-fold serial dilution of compounds in 161 
96-well microtitre plates, giving a typical final concentration range of 0.25-128 µg/mL and a 162 
maximum final concentration of 1% DMSO. Strains were grown in cation-adjusted Müller-163 
Hinton broth (CA-MHB) or agar (CA-MHA) with or without 5% lysed horse blood at 37°C in an 164 
ambient atmosphere, in haemophilus testing medium broth at 37°C in an ambient atmosphere, 165 
or in gonococcal broth or agar supplemented with Vitox at 37°C in an atmosphere containing 166 
5% CO2. The MIC was determined as the lowest concentration of compound that inhibits 167 
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visible growth following a 16-24 h incubation period. For Mycobacterium tuberculosis, a 168 
fluorescent reporter strain of H37Rv was used and the MIC was determined by measuring the 169 
optical density (OD590) or fluorescence (Ex 560 nm/Em 590 nm) after five days of growth in 170 
7H9 broth with 10% v/v OADC supplement and 0.05 % w/v Tween 80 in the presence of test 171 
compound with a final DMSO concentration of 2 %. MIC90 determination was performed at 172 
IHMA Europe Sàrl (Epalinges, Switzerland) with a selection of clinical isolates collected 173 
between 2012 and 2014. Bacteria were obtained from a variety of infection types and 174 
geographical locations including at least 25% highly drug-resistant isolates (resistant to at 175 
least seven out of amikacin, aztreonam, cefepime, ceftazidime, ceftriaxone, colistin, 176 
gentamicin, imipenem/meropenem, levofloxacin, piperacillin-tazobactam and tetracycline) 177 
and with a selection of 10 different species of anaerobes, including 113 isolates collected in 178 
2015 from diverse geographical origins. MICs were performed using frozen 96-well 179 
antibacterial panels prepared by broth microdilution in line with the guidelines of the Clinical 180 
and Laboratory Standards Institute M11-A8 (25), giving a final compound concentration range 181 
of 0.004 to 64 µg/mL. The inoculum size was 5 × 105 CFU/mL and 5 × 107 CFU/mL for the 182 
aerobic and anaerobic strains, respectively. The testing plates for anaerobes were incubated 183 
for 48 h at 35 °C with 5% CO2 in an anaerobic cabinet (Whitley A35 anaerobic workstation, 184 
Don Whitley Scientific). MICs were read visually and values were reported as MIC90 for 185 
inhibition of 90% of the isolates. MIC testing of Bacillus anthracis, Burkholderia mallei, 186 
Burkholderia pseudomallei, Francisella tularensis and Yersinia pestis was undertaken by 187 
Southern Research (Birmingham, Alabama). Assay medium was CA-MHB (supplemented 188 
with 2% IsoVitalex in the case of F. tularensis). Cultures were incubated in the presence of 189 
compound for up to 24 h, up to 38 h (F. tularensis) or 24-48 h (Y. pestis). 190 
 191 
Synergy/antagonism experiments. Antibacterial combinations were assessed using a two-192 
dimensional checkerboard MIC method. Interpretation of the fractional inhibitory concentration 193 
index (FICI) was as described by Odds (26). Results shown are representative of at least two 194 
independent experiments.  195 
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 196 
Time-of-kill. The rate of bactericidal activity of compounds was determined against A. 197 
baumannii NCTC 13420 at 4 × MIC according to guidelines of the Clinical and Laboratory 198 
Standards Institute M26-A (27). A. baumannii was cultured overnight at 37°C, diluted in fresh 199 
CA-MHB and grown to exponential phase (OD600nm = 0.3). Cultures were then adjusted to 0.5 200 
McFarland units (1-2 × 108 CFU/mL) before addition of compound to give a final concentration 201 
of 4 × MIC. Samples were taken at 0, 0.5, 1, 3, 6 and 24 h, serial diluted and plated onto MHA, 202 
followed by overnight incubation at 37°C. The following day, colonies were enumerated to 203 
determine CFU/mL.  204 
 205 
Frequency of resistance. Overnight cultures of bacteria were grown from single colonies in 206 
CA-MHB. The following day, samples of the neat cultures were spread onto CA-MHB 207 
containing compound at the concentrations indicated. To determine the number of viable cells 208 
in the inoculum, samples of the overnight cultures were serially diluted in phosphate-buffered 209 
saline (PBS) and plated on compound-free CA-MHA. Plates were incubated for up to 48 h and 210 
the colonies were enumerated. The spontaneous frequency of resistance (FoR) was 211 
calculated by dividing the number of resistant colonies (CFU/mL) by the total number of viable 212 
cells (CFU/mL). 213 
 214 
Selection of resistant mutants by serial passage. Resistant mutants were selected by 215 
serial passage carried out using the broth microdilution method. Following MIC determination 216 
the culture representing 0.25 × MIC was used to inoculate the subsequent until the desired 217 
level of resistance was achieved. At this point, clones were isolated and the MIC confirmed as 218 
described above. 219 
Whole-genome sequencing. Genomic DNA (gDNA) was extracted from the resistant strains 220 
using the PurElute Bacterial Genomic Kit (Edge BioSystems, Gaithersburg, Maryland). The 221 
gDNA was purified according to the manufacturer’s instructions. Whole genome sequencing 222 
was performed at the Next Generation Sequencing facility at the University of Leeds (Leeds, 223 
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United Kingdom). Purified gDNA was used to create whole genome libraries using NEBNext 224 
Ultra kit and 150 bp paired end read sequence data were produced using an Illumina HiSeq 225 
3000. Read data were stored as FASTQ files and then adaptor sequences were removed 226 
using cutadapt software (Version 1.8). Data for the wild-type strain was used to construct a 227 
reference genome sequence using the CLCBio genome assembler (Version 8.0.1). Sequence 228 
data for each sample, including the progenitor strain, were aligned to the published E. coli 229 
ATCC 25922 genome using BWA (Version 0.7.12); aligned data and were sorted using 230 
Samtools6 (Version 1.2).  Variants were identified using VarScan (Version 2.3.7) using the E. 231 
coli ATCC 25922 assembled genome as the reference sequence. The resulting data provided 232 
coverage of >100 reads across the genome. Single nucleotide polymorphisms (SNPs), 233 
insertions and deletions were identified that were prevalent in ≥95% of the reads compared 234 
with the progenitor strain. 235 
 236 
Cytotoxicity testing. HepG2 cells (ATCC HB-8065) were seeded at a density of 20,000 cells 237 
per well and incubated for 24 h at 37°C in an atmosphere of 5% CO2. Cells were then exposed 238 
to a doubling dilution series of the test compound. After 24 h of incubation, the viability of the 239 
cells was determined using CellTiter-Glo® (Promega, WI, USA), according to the 240 
manufacturer’s instructions. Each experiment was carried out in duplicate and the results 241 
reported as the average concentration of test compound inhibiting 50% of cell viability (IC50). 242 
 243 
hERG Inhibition. Inhibition of the human Ether-a-go-go Related Gene (hERG) cardiac 244 
potassium (K+) ion channel was determined in a transfected Chinese Hamster Ovary K1 245 
(CHO) cell line using IonWorks patch clamp electrophysiology (28). 246 
 247 
LogD measurements. Partitioning of compounds between 1-octanol and 0.1 M phosphate 248 
buffer (pH 7.4) was measured using the shake-flask method (29).  249 
 250 
 251 
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 252 
 253 
 254 
 255 
 256 
 257 
 258 
 259 
 260 
 261 
 262 
 263 
 264 
 265 
 266 
 267 
 268 
 269 
 270 
 271 
 272 
 273 
 274 
 275 
RESULTS 276 
 277 
Inhibition of target activity in vitro. The five compounds tested potently inhibited both E. 278 
coli DNA gyrase and topoisomerase IV enzymes, consistent with a dual-targeting mechanism-279 
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of-action (Table 1). Ciprofloxacin was selected as a representative quinolone and tested in 280 
parallel for comparison. REDX05777, REDX06181, REDX06213, REDX07623 and 281 
REDX07638 produced a range of IC50 values comparable with ciprofloxacin in the supercoiling 282 
assay, while all five compounds showed approximately 10-fold lower IC50 values than 283 
ciprofloxacin in the decatenation assay. Stabilisation of the DNA gyrase cleavage complex 284 
was observed in the presence of ciprofloxacin (35% at 100 µM), while all Redx compounds 285 
showed little or no stabilisation of this complex at the same concentration. Taken together, 286 
these results indicate that the Redx compounds potentially have a more balanced dual 287 
targeting activity than ciprofloxacin and a distinct mechanism-of-action. Similar to 288 
ciprofloxacin, Redx compounds showed a high degree of selectivity for the bacterial enzymes 289 
over the homologous mammalian enzyme, human topoisomerase II, with approximately two 290 
orders of magnitude difference in the measured IC50 values (Table 1).   291 
 292 
Bacterial susceptibility profile. Bacterial susceptibility profiling of the NBTI compounds 293 
indicates that the series has broad-spectrum activity against clinically-important Gram-294 
negative and Gram-positive pathogens, including those of the ‘ESKAPE’ group of 295 
microorganisms (Table 2). Compounds from the series were generally more potent against 296 
the Gram-positive species. Fastidious Gram-negatives, such as Haemophilus infuenzae and 297 
Neisseria gonorrhoeae, as well as non-fastidious Gram-negatives species were susceptible 298 
to the compounds. Of the non-fastidious Gram-negatives, Acinetobacter baumannii and E. coli 299 
were generally more susceptible than Enterobacter cloacae, Klebsiella pneumoniae and 300 
Pseudomonas aeruginosa. Representative compound REDX05777 also potently inhibited the 301 
whole-cell proliferation of Mycobacterium tuberculosis (Table 2). The exemplar compound 302 
REDX07638 was tested against a set of five biothreat micro-organisms that included the 303 
aetiological agents of anthrax, Glanders, meliodosis, tularaemia and the plague (Table 3). 304 
REDX07638 inhibited all five Gram-positive and Gram-negative species, with Bacillus 305 
anthracis, Francisella tularensis and Yersinia pestis being the most susceptible. 306 
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Compounds retained potency against the E. coli strains, MG1655 S83L and MG1655 D87G, 307 
carrying the Ser83Leu and Asp87Gly mutations in the GyrA subunit of DNA gyrase that are 308 
associated with quinolone resistance. In all cases the MIC for the mutants was within one-309 
doubling-dilution either side of the MIC for the isogenic parent strain E. coli MG1655. By 310 
contrast, the MIC of ciprofloxacin increased 8-16-fold against the MG1655 S83L and MG1655 311 
D87G strains compared to the isogenic parent (Table 2). E. coli ECCPX1-SP25 is a 312 
ciprofloxacin-resistant mutant derived from the wild-type parent strain ATCC 25922. The MIC 313 
of ciprofloxacin against this strain is elevated 1024-fold relative to the parent strain. In 314 
comparison, the activity of Redx compounds against E. coli ECCPX1-SP25 was within 2-to-8-315 
fold of strain ATCC 25922 (Table 2). Taken together, these results indicate a lack of cross-316 
resistance of the NBTI series with the quinolone class of antibiotics.  317 
A selection of Redx compounds were tested against a panel of recent multidrug-resistant 318 
(MDR) and quinolone-resistant Gram-negative clinical isolates (Table 4). All three compounds 319 
tested showed antibacterial activity against E. coli with a MIC90 of 4 or 8 µg/mL. Similarly, good 320 
activity was observed with REDX07623, REDX06213 and REDX06276 against A. baumannii 321 
with MIC90 of 4 or 8 µg/mL. The MIC90 values observed for these NBTI compounds against E. 322 
coli and A. baumannii were lower than those obtained for the fluoroquinolone antibiotic 323 
levofloxacin (16 µg/mL). REDX06276 was the most active compound from this series against 324 
the K. pneumoniae panel with a MIC90 of 16 µg/mL, comparable to levofloxacin. Activity 325 
against P. aeruginosa and E. cloacae was observed at 32-to-64 µg/mL for all compounds 326 
tested, which was similar to the MIC90 values obtained for levofloxacin. 327 
Finally, compounds were tested for activity against species of clinically-significant obligate 328 
anaerobic Gram-positive and Gram-negative bacteria. Antibiotics of the quinolone class have 329 
generally shown poor-to-moderate in vitro antibacterial potency against anaerobic bacteria 330 
relative to other classes of antibiotics and compared with their potency against aerobic 331 
bacteria (30, 31). Metronidazole and vancomycin were equally effective against a panel of 332 
recently-isolated anaerobes including the Gram-positive strains of P. harei, P. anaerobius and 333 
C. perfringens with MIC90 values lower or equal to 2 µg/mL (Table 5). Metronidazole, however, 334 
13 
 
was not active against P. acnes while the Redx compounds maintained activity with MIC90 335 
values of 0.5 and 4 µg/mL. Similar to ciprofloxacin, the tested compounds showed reduced 336 
activity against the Gram-positive strains of F. magna and P. micra with MIC90 values 16-64 337 
µg/mL. Against the Gram-negative isolates, Redx compounds showed activity at 2-to-16 338 
µg/mL against the four bacterial species tested. Although metronidazole displayed lower MIC90 339 
values (0.25-to-2 µg/mL), the NBTI compounds showed improved activity compared to 340 
ciprofloxacin and vancomycin.     341 
 342 
Antibiotic combination studies. Since co-administration of antibiotics acting on different 343 
targets can enhance antibacterial activity, REDX07638 was tested in combination with 344 
ampicillin and delafloxacin against several Gram-negative strains including those conferring 345 
resistance to β-lactam and fluoroquinolone antibiotics. An FICI was calculated and interpreted 346 
as described previously (26). A FICI of 0.5 was calculated for REDX07638 in combination with 347 
ampicillin against β-lactam resistant E. coli NCTC 13476 indicating synergism. This 348 
combination showed an FICI of 2 against other β-lactam strains indicating no interaction. 349 
Additionally, REDX07638 in combination with delafloxacin showed an FICI of 0.75-1.25 350 
against fluoroquinolone resistant (FQR) strains E. coli ECDEL-SP45 and K. pneumoniae 351 
ATCC 13439, indicating no interaction. These results suggest REDX07638 in combination 352 
with ampicillin or delafloxacin could be used given the lack of antagonism observed. 353 
 354 
Time of kill. The rate of bactericidal activity was determined for REDX06213, REDX06276, 355 
REDX07623 and REDX07638 against A. baumannii NCTC 13420 at 4 × MIC. REDX06213 356 
and REDX06276 both demonstrated bactericidal activity, showing a 3-log drop in CFU/mL at 357 
1.56 and 1.06 h, respectively. A 3-log reduction in CFUs was not achieved within 24 h with 358 
REDX07623 and REDX07638 at 4 × MIC against this strain. All compounds showed regrowth 359 
at 24 h. Bactericidal activity of ciprofloxacin against A. baumannii has been documented in the 360 
literature and demonstrates a 3-log drop in CFU/mL at 4× MIC, with no significant regrowth at 361 
24 h (32).  362 
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 363 
Selection of resistant mutants. In order to assess the propensity for the development of de 364 
novo resistance to this class of NBTI compounds, the spontaneous frequency of resistance to 365 
REDX06213, REDX06276, REDX07623 and REDX07638 was determined with E. coli strain 366 
ATCC 25922. No mutants could be isolated at concentrations equivalent to 4× MIC, yielding 367 
frequencies-of-resistance ranging from <2.5 × 10-9 to <3.3 × 10-9. By comparison, the 368 
frequency-of-resistance to ciprofloxacin at 4 × MIC was 7.8 × 10-8 for E. coli ATCC 25922. To 369 
confirm that the observed mutation frequencies were not species-specific, frequencies-of-370 
resistance values were also determined for REDX06213, REDX07623 and REDX07638 in A. 371 
baumannii strain NCTC 13420. Again, no mutants were isolated, yielding frequencies-of-372 
resistance between <6.7 × 10-8 and <7.4 × 10-8. 373 
Next, E. coli ATCC 25922 was used in serial passage experiments with REDX06276 as a 374 
representative compound from this NBTI series. Ciprofloxacin and delafloxacin were used as 375 
comparator antibiotics. The MIC of ciprofloxacin increased up to 64 µg/mL after 25 passages 376 
with resistance observed at passage 23 (MIC ≥ 4 µg/mL). The MIC of delafloxacin, however, 377 
remained within 2-fold of the original MIC (0.5 µg/mL) up to passage 24, after which it 378 
increased steadily to reach 16 µg/mL (32-fold increase) at passage 45. The MIC of 379 
REDX06276 followed a comparable trend to delafloxacin with an increase up to 32-fold (MIC 380 
64 µg/mL) at passage 45, at which stage the experiment was ended (Figure 2). Whole genome 381 
sequencing of the ciprofloxacin resistant mutant from passage 25 (ECCPX1-SP25) revealed 382 
Ser83Leu and Asp87Gly mutations in the GyrA subunit and a Glu84Lys mutation in the ParC 383 
subunit. The delafloxacin-resistant mutant at passage 45 had target gene mutations 384 
corresponding to Ala119Glu and Ala179Val amino acid substitutions in the GyrA subunit. The 385 
REDX06276-resistant mutant from passage 45 carried a single Arg38Leu substitution in the 386 
GyrA subunit.  387 
 388 
In vitro safety profile. Mammalian cytotoxicity testing with the HepG2 cell line revealed IC50 389 
values that were higher than the corresponding MIC values observed with the ESKAPE 390 
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pathogens (Table 6). For some compounds the therapeutic window exceeded two orders of 391 
magnitude. In vitro testing showed the series to have a range of hERG activity (Table 6), with 392 
REDX07623 having an IC50 of 8.2 µM, whilst REDX6181 demonstrated reduced hERG 393 
inhibition with an IC50 of >100 µM. A correlation between logD and hERG activity was found 394 
with this series. Compounds with a lower logD appeared to have reduced hERG inhibition 395 
(Table 6).   396 
 397 
 398 
 399 
 400 
 401 
 402 
 403 
 404 
 405 
 406 
 407 
 408 
 409 
 410 
 411 
 412 
DISCUSSION 413 
 414 
In recent years the growing threat of drug-resistant bacterial infections and the lack of new 415 
antibiotics with a novel mechanism-of-action has caused global concern. Resistance of Gram-416 
negative species to first line and last resort antibiotics has been reported worldwide and can 417 
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lead to untreatable infections and increased mortality (33). To address this unmet medical 418 
need, this study describes the in vitro assessment of an NBTI series with dual-targeting activity 419 
against bacterial DNA gyrase and topoisomerase IV and a different mechanism-of-action to 420 
clinically used fluoroquinolones. Redx compounds demonstrated potent, balanced inhibitory 421 
activity versus the two topoisomerase enzymes, with IC50 values ranging from 0.21 to 1.66 µM 422 
with E. coli DNA gyrase and between 0.10 and 1.17 µM against E. coli topoisomerase IV 423 
(Table 1). Inhibitory activity was more balanced than ciprofloxacin, which had IC50 values of 424 
0.77 and 10.20 µM against E. coli gyrase and topoisomerase IV, respectively. This is in 425 
agreement with data recorded in the literature, which shows ciprofloxacin to have a preference 426 
for DNA gyrase in E. coli and topoisomerase IV in S. aureus (34). Importantly, selectivity over 427 
human topoisomerase II was found with bacterial enzymes showing an approximate 100-fold 428 
increase in sensitivity to Redx compounds. The formation of DNA cleaved complexes was 429 
limited with Redx compounds in comparison to the level observed with ciprofloxacin (Table 1). 430 
This indicates that the NBTI series described here has a different mechanism-of-action to 431 
ciprofloxacin, which stabilises double-stranded broken DNA strands, blocking re-ligation, the 432 
consequences of which are poisonous to the bacterial cell. Instead, the NBTIs described here 433 
interact with the topoisomerase and DNA prior to double strand breakage, which has been 434 
reported for other NBTI series (18). 435 
Broad-spectrum antibacterial activity was found with this series against a panel of ESKAPE 436 
pathogens, the fastidious Gram-negative organisms H. influenzae and N. gonorrhoeae, as 437 
well as M. tuberculosis and important Gram-positive and Gram-negative biothreat pathogens 438 
(Table 2 and 3). Potency was maintained against FQR E. coli isolates with a single amino acid 439 
substitution in the GyrA subunit (Ser83Leu or Asp87Gly) with MICs within two-fold of the MIC 440 
for the isogenic parent strain. Additionally, compounds retained potency against the serial 441 
passage FQR mutant E. coli ECCPX1-SP25, with MICs increasing eight-fold or less, in 442 
comparison to ciprofloxacin which showed a 1024-fold increase in MIC. The retained potency 443 
of this series against FQR mutants supports the different mechanism-of-action to the 444 
fluoroquinolones indicated by the cleavage complex enzyme assay. Good antibacterial activity 445 
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was retained against a larger panel of MDR strains (25% levofloxacin resistant) of A. 446 
baumannii and E. coli, with MIC90 values of 4-8 µg/mL. A loss of potency was found against 447 
the other Gram-negative strains, K. pneumoniae, E. cloacae and P. aeruginosa, with MIC90 448 
values of 16-32 µg/mL, although these were still equal to or superior to levofloxacin and other 449 
fluoroquinolones reported in the literature (35). In addition to good activity against ESKAPE 450 
pathogens, compounds demonstrated antibacterial activity against a panel of anaerobic 451 
pathogens including Clostridium and Bacteroides species (Table 2 and 5). In Europe, C. 452 
difficile is estimated to cause 250,000 infections and 14,000 deaths per annum, showing 453 
resistance to a large number of antibiotics including the fluoroquinolones (36). Bacteroides 454 
species are part of the mammalian gut microflora and can be opportunistic pathogens as well 455 
as a reservoir for resistance. They are also frequently resistant to a wide range of antibiotics, 456 
necessitating development of novel compounds that are effective against these species.. 457 
A representative compound, REDX07638, was tested in combination with ampicillin and 458 
delafloxacin against several resistant Gram-negative strains and showed no antagonism, 459 
suggesting that this series of compounds could potentially be used in combination therapy. 460 
This finding has been reported previously with other bacterial topoisomerase II inhibitors in 461 
combination with other antibiotics (37, 38, 39). Interestingly, REDX07638 and ampicillin 462 
demonstrated a synergistic interaction against E. coli NCTC 13476, but this was not 463 
consistently observed for other β-lactam resistant strains.  464 
Rapid, bactericidal activity of the series was confirmed with REDX06213 and REDX06276 465 
against A. baumannii NCTC 13420 at 4 × MIC, with both compounds causing a 3-log drop in 466 
CFU/mL at 1.56 and 1.06 h, respectively. The rate of bactericidal activity was similar or 467 
superior to that for ciprofloxacin and other NBTIs reported in the literature (32, 40, 41).  468 
No mutants were raised against compounds tested at 4 × MIC with A. baumannii NCTC 13420 469 
and E. coli ATCC 25922. By contrast, a mutation rate of 4.76 x 10-8 was obtained with E. coli 470 
ATCC 25922 against ciprofloxacin at equivalent multiples of its MIC. These results indicate a 471 
low potential for resistance development to this series and support the balanced dual-targeting 472 
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activity revealed by the supercoiling and decatenation assay data. Development of resistance 473 
to other NBTI series at 4 × MIC has been reported in the literature. Resistance rates of 5 × 10-474 
8 were found with NBTI 5463 against P. aeruginosa PAO1, although sequencing showed no 475 
target gene mutations (18). Second- and third-step mutants had Asp82Glu and Asp82Glu plus 476 
Asp87Tyr point mutations in GyrA, respectively (42). These mutants showed no cross-477 
resistance to the fluoroquinolones consistent with a differential binding mechanism between 478 
the NBTI and fluoroquinolone classes of topoisomerase inhibitors. Although no mutants were 479 
raised during the spontaneous frequency-of-resistance experiments against the compounds 480 
described here, whole genome sequencing of the E. coli REDX06276 serial passage mutant 481 
revealed a single Arg38Leu substitution in the GyrA subunit. This mutation has been reported 482 
previously and conferred resistance to 5,6-bridged quinolones, but not other quinolones (43). 483 
Similarly, no cross-resistance to ciprofloxacin was found with the E. coli REDX06276 serial 484 
passage mutant (data not shown).  485 
Compounds in this series show a promising safety profile with HepG2 cytotox IC50 values of 486 
≥32 µg/mL. Reduced hERG activity with the series has also been demonstrated, with IC50 487 
values of >100 µM. During the optimisation of this series, efforts have been made to reduce 488 
hERG effects while retaining antibacterial potency. The addition of a fluorine atom in the 489 
southern group of REDX07623 appears to increase the hERG activity in comparison to its 490 
matched pair, REX06276, with IC50 values of 8.2 and >33 µM, respectively. Introduction of 491 
more polar groups to reduce the logD of a compound, thereby reducing hERG activity, has 492 
been reported for NBTIs previously in the literature (22). REDX06181, with the lowest logD of 493 
the compounds tested, showed the most attenuated hERG activity with an IC50 of >100 µM, 494 
although relative to other compounds with a higher logD, such as REDX07623, its antibacterial 495 
potency was reduced. A negative correlation between whole-cell antibacterial potency and 496 
hERG activity has been reported for other NBTI type compounds (22). 497 
In summary, the NBTI series described here shows potent, balanced, dual-targeting inhibition 498 
of DNA gyrase and topoisomerase IV, with selectivity over human topoisomerase II. Data from 499 
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DNA cleaved complex experiments indicates the series has a different mechanism-of-action 500 
to the fluoroquinolones. The low mutation rate of Gram-negative strains to the compounds 501 
combined with the balanced inhibitory enzyme activity suggests resistance could be slow to 502 
develop during therapeutic use. Antibacterial activity was demonstrated against a wide panel 503 
of susceptible and drug-resistant bacterial species including the ESKAPE set of organisms, 504 
medically-important anaerobic species and other pathogens, including larger sets of MDR 505 
isolates thereof. Rapid, bactericidal activity was also demonstrated. These properties, in 506 
combination with the promising in vitro safety profile, warrants the further development of this 507 
NBTI series. 508 
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TABLE 1 Inhibition of the DNA supercoiling and cleaved complex formation activities of E. coli 710 
DNA gyrase, the decatenation activity of E. coli topoisomerase IV, and the decatenation 711 
activity of human topoisomerase II by ciprofloxacin, REDX06181 and REDX06213. 712 
 Ciprofloxacin 
REDX 
05777 
REDX 
06181 
REDX 
06213 
REDX 
07623 
REDX 
07638 
E. coli DNA gyrase IC50 (µM) 0.77 0.29 1.47 1.66 0.21 0.23 
E. coli DNA gyrase cleavage complex (% 
cleaved)  
35.0 0 2.6 3.5 0 0 
E. coli topoisomerase IV IC50 (µM) 10.20 0.25 1.17 0.14 0.10 0.10 
Human topoisomerase II IC50 (µM) 500 >100 84 100 >100 100 
 713 
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 729 
TABLE 2 Bacterial susceptibility profile of NBTI compounds against reference bacterial strains 730 
and fluoroquinolone mutants. 731 
Species and 
strain 
MIC (µg/mL) 
Ciprofloxacin 
REDX 
05777 
REDX 
06181 
REDX 
06213 
REDX 
06276 
REDX 
07623 
REDX 
07638 
Acinetobacter 
baumannii 
NCTC 13420 
64 2 16 0.12 0.25 0.25 0.25 
Clostridium 
difficile  
ATCC 700557 
16 n.d. n.d. 2 n.d. 2 n.d. 
28 
 
Enterobacter 
cloacae 
NCTC 13406 
0.015 8 8 2 1 2 2 
Enterococcus 
faecalis 
ATCC 29212 
1 2 2 1 0.5 1 1 
Escherichia 
coli 
ATCC 25922 
0.03 0.5 1 0.12 0.25 0.5 0.5 
E. coli 
MG1655  
WT 
0.008 0.5 1 0.25 0.5 0.5 0.5 
E. coli 
MG1655  
S83L 
0.12 0.5 0.5 0.25 0.25 0.25 0.25 
E. coli 
MG1655  
D87G 
0.06 1 0.5 0.5 1 1 1 
E. coli  
ECCPX1- 
SP25 
32 4 1 1 0.5 1 2 
Haemophilus 
influenzae 
ATCC 49247 
0.008 4 4 2 2 4 2 
Klebsiella 
pneumoniae 
ATCC 700603 
0.25 16 32 8 8 8 8 
Mycobacterium 
tuberculosis 
H37Rv 
2.2 1.3 n.d. n.d. n.d. n.d. n.d. 
29 
 
Nesisseria 
gonorrhoeae 
ATCC 49226 
0.004 4 16 2 1 2 2 
Pseudomonas 
aeruginosa 
ATCC 27853 
1 8 8 4 4 8 4 
Staphylococcus 
aureus 
ATCC 29213 
0.25 1 4 0.12 0.25 0.5 0.12 
Streptococcus 
pneumoniae 
ATCC 49619 
0.5 2 4 0.5 0.25 0.5 0.25 
n.d., not determined 732 
 733 
 734 
 735 
 736 
 737 
TABLE 3 Susceptibility profile of a panel of biodefence pathogens to REDX07638 and the 738 
comparator antibiotic doxycycline. 739 
Species and strain MIC (µg/mL) 
Doxycycline REDX07638 
Bacillus anthracis Ames 0.03 0.5 
Burkholderdia mallei China 7 0.12 8 
Burkholderdia pseudomallei DD503 2 32 
Burkholderdia pseudomallei K96243 2 32 
Burkholderdia pseudomallei 1026b 1 16 
Francisella tularensis SCHU S4 0.5 4 
Yersinia pestis CO92 2 1 
30 
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TABLE 4 MIC90 (µg/mL) of NBTI compounds and levofloxacin for a panel of recently isolated 757 
levofloxacin-resistant and multidrug-resistant clinical isolates. 758 
Species 
(number of isolates) 
MIC90 (µg/mL) 
Levofloxacin REDX06213 REDX06276 REDX07623 
K. pneumoniae 
(42) 
16 32 16 32 
A. baumannii 
(43) 
16 8 8 4 
P. aeruginosa 
(42) 
64 32 32 32 
31 
 
E. cloacae 
(41) 
32 32 32 32 
E. coli 
(43) 
16 4 4 8 
 759 
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 762 
 763 
 764 
 765 
 766 
 767 
 768 
 769 
 770 
 771 
TABLE 5 Bacterial susceptibility profile of NBTI compounds and comparator antibiotics 772 
against a panel of recent clinical isolates of 10 anaerobic bacterial species. 773 
Species  
(number of isolates) 
MIC90 (µg/mL) 
Metronidazole Vancomycin Ciprofloxacin REDX06213 REDX07623 
Clostridium 
perfringens (11) 
1 0.5 0.5 2 2 
Finegoldia  
magna (12) 
0.5 0.5 32 16 32 
Parvimonas  
micra (12) 
1 1 16 64 64 
32 
 
Peptostreptococcus 
anaerobius (10) 
0.5 0.5 16 0.25 1 
Propionibacterium 
acnes (12) 
>32 0.5 1 0.5 4 
Peptoniphilus  
harei (12) 
1 0.12 4 ≤0.12 0.5 
Bacteroides 
fragilis (12) 
0.5 32 16 4 4 
Bacteroides 
thetaiotaomicron (11) 
1 64 64 16 8 
Prevotella 
bivia (10) 
2 >64 32 8 8 
Prevotella 
melaninogenica (11) 
0.25 >64 4 2 4 
 774 
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 777 
TABLE 6 In vitro safety profile of NBTI compounds and ciprofloxacin. 778 
 
REDX 
05777 
REDX 
06181 
REDX 
06213 
REDX 
06276 
REDX 
07623 
REDX 
07638 
HepG2  
IC50 (µg/mL) 
>64 >64 29.6 >64 >64 38 
hERG  
IC50 (µM) 
>33 >100 >33 >33 8.2 8.9 
logD 0.65 -0.64 0.94 0.71 1.26 1.39 
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FIGURE 1 Chemical structures of the compounds described in this study. 798 
    799 
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FIGURE 2 Isolation of drug-resistant mutants of E. coli ATCC 25922 by serial passage. Closed 808 
circles, REDX06276; open triangles, ciprofloxacin; open squares, delafloxacin. 809 
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